Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 19/20 | 0.54 |
| ▸ | PDE4A | P27815 | 1/20 | 0.54 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | HTR7 | P34969 | 1/20 | 0.41 |
| ▸ | HTR6 | P50406 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5868188 | 0.86 | PDE4B (0.47) | PDE4BPDE4APDE4DCYP3A4 | |
| SCHEMBL8297678 | 0.84 | PDE4B (0.61) | PDE4BPDE4APDE4DCYP3A4 | |
| SCHEMBL5867991 | 0.82 | PDE4B (0.50) | PDE4BPDE4APDE4DCYP3A4 | |
| SCHEMBL5432120 | 0.81 | PDE4B (0.47) | PDE4BPDE4APDE4DCYP3A4 | |
| SCHEMBL5753794 | 0.81 | PDE4B (0.57) | PDE4BPDE4APDE4D | |
| SCHEMBL8295429 | 0.81 | PDE4B (0.58) | PDE4BPDE4APDE4DCYP3A4 | |
| SCHEMBL5753289 | 0.81 | PDE4B (0.49) | PDE4BPDE4APDE4DCYP3A4 | |
| SCHEMBL5749094 | 0.80 | PDE4B (0.71) | PDE4BPDE4APDE4D | |
| SCHEMBL5752494 | 0.80 | PTGER4 (0.51) | PDE4BPDE4APDE4DCYP3A4HTR1A | |
| SCHEMBL5752938 | 0.80 | PDE4B (0.57) | PDE4BPDE4APDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7056934-B2 | Nicotinamide derivatives useful as PDE4 inhibitors | PFIZER INC (US) | 2006-06-06 | — | — | US | claimed |
| EP-1654234-A1 | NICOTINAMIDE DERIVATIVES USEFUL AS PDE4 INHIBITORS | Pfizer Limited (GB) | 2006-05-10 | — | — | EP | claimed |
| US-20050038033-A1 | Nicotinamide derivatives useful as PDE4 inhibitors | PFIZER INC | 2005-02-17 | — | — | US | claimed |
| WO-2005009965-A1 | NICOTINAMIDE DERIVATIVES USEFUL AS PDE4 INHIBITORS | PFIZER LIMITED (GB) | 2005-02-03 | — | — | WO | claimed |
| US-7056934-B2 | Nicotinamide derivatives useful as PDE4 inhibitors | PFIZER INC (US) | 2006-06-06 | — | — | US | disclosed |
| US-20050038033-A1 | Nicotinamide derivatives useful as PDE4 inhibitors | PFIZER INC | 2005-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038033-A1 | Nicotinamide derivatives useful as PDE4 inhibitors | PDE4A, PDE4B, PDE4C | PDE4B 2/4885PDE4A 1/4885PDE4D 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.